Endocrine signaling research
Ipamorelin
Lyophilisiertes Peptid zur Forschung zu endokrinen Signalen zur Systemüberprüfung
Ipamorelin is a selective growth hormone secretagogue receptor research peptide used in GH-release and endocrine-signaling comparisons.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesNur für Laborforschungszwecke. Nicht für den menschlichen oder veterinärmedizinischen Gebrauch bestimmt. Nicht zur Diagnose, Behandlung, Heilung, Linderung oder Vorbeugung von Krankheiten bestimmt.
Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.
Verpackt für Transportstabilität mit Bestellunterstützung für Routen bei warmem Wetter.
Batch-linked certificate support is available through the documentation desk.
Forschungskontext
Ipamorelin Forschungsprofil
Ipamorelin is a pentapeptide growth hormone secretagogue studied for activity at the ghrelin receptor, also known as GHS-R1a. Experimental work compares GH-release response, pharmacokinetics, receptor selectivity, and effects on other endocrine markers with older secretagogues such as GHRP-2, GHRP-6, and hexarelin. It differs from CJC-1295 and sermorelin because those compounds act through the GHRH receptor rather than GHS-R. Ipamorelin is therefore a focused choice for secretagogue and receptor-selectivity studies, either alone or as a comparator in GH-axis designs. Early human PK/PD literature exists, but it does not validate a research-use catalog lot.
Vorgeschlagener Mechanismus
A pentapeptide agonist at the growth-hormone secretagogue receptor GHS-R1a. Receptor activation engages Gq-related signaling in pituitary and hypothalamic systems and stimulates growth-hormone release.
In Studien berichtete Effekte
- Animal and human pharmacology studies reported dose-dependent GH release after ipamorelin exposure.
- Comparative studies described greater GH selectivity and less ACTH or cortisol stimulation than some older GHRP compounds under studied conditions.
- It remains a ghrelin-receptor agonist, and selectivity does not mean absence of all off-target or systemic effects.
Häufige Forschungsendpunkte
GHS-R1a potency, calcium or second-messenger response, GH concentration and pulse shape, ACTH, cortisol, prolactin, appetite markers, pharmacokinetics, and desensitization.
Evidenz und Grenzen
Preclinical and early controlled human PK/PD evidence exists. Long-term human outcomes and equivalence of catalog material are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.